A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases
Zozaya, Néboa ![Identificador ORCID](/img/uab/orcid.ico)
(Universidad de Las Palmas de Gran Canaria)
Arrizubieta Basterrechea, M.I. (Hospital de Galdakao (Usansolo, Biscaia))
Bollo, E. (Complejo Asistencial Universitario de León)
Castellvi, Ivan ![Identificador ORCID](/img/uab/orcid.ico)
(Institut d'Investigació Biomèdica Sant Pau)
Espín, J. (Andalusian School of Public Health)
Ortego, N. (Hospital Universitario San Cecilio (Granada))
Poveda-Andrés, J.L. (Hospital Universitari i Politècnic La Fe (València))
Rodríguez Portal, J.A. (Centro de Investigación Biomédica en Red - Enfermedades Respiratorias (CIBERES))
Rivero, A. (Bioregión de Salud y Bienestar (BioMad))
Marcos-Rodríguez, J.A. (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Verde, L. (Integrated Health Area)
Universitat Autònoma de Barcelona
Data: |
2022 |
Resum: |
Objectives Our aim was to assess the value of nintedanib for non-idiopathic progressive fibrosing interstitial lung disease (non-IPF PF-ILD) and systemic sclerosis-associated ILD (SSc-ILD) in the Spanish context, using a multi-criteria decision analysis (MCDA). Methods Following an adaptation of the Evidence and Value: Impact on DEcision Making (EVIDEM) MCDA methodology, the estimated value of nintedanib was obtained by means of an additive linear model that combined individual weights (100-points distribution) of criteria with the individual scoring of nintedanib in each criterion for every indication, assigned by a multidisciplinary committee of twelve clinicians, patients, pharmacists, and decision-makers. To assess the reproducibility, an alternative weighting method was applied, as well as a re-test of weights and scores at a different moment of time. Results The experts committee recognized nintedanib as an intervention with a positive value contribution in comparison to placebo for the treatment of non-IPF PF-ILD (0. 50 ± 0. 16, on a scale from -1 to 1) and SSc-ILD (0. 40 ± 0. 12), diseases which were considered as very severe and with high unmet needs. The drug was perceived as a treatment that provides an added therapeutic benefit for patients (0. 06-0. 07), given its proven clinical efficacy (0. 05-0. 06), slight improvements in patient-reported outcomes (0. 01-0. 02), and similar safety profile than placebo (-0. 04-0. 00), which will likely be positioned as a recommended therapy in the next clinical practice guidelines updates. Conclusions Under this increasingly used methodology, nintedanib has shown to provide a positive value estimate for non-IPF PF-ILD and SSc-ILD when compared to placebo in Spain. |
Drets: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. ![Creative Commons](/img/licenses/by.ico) |
Llengua: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Matèria: |
Interstitial lung diseases ;
Multi-criteria decision analysis ;
Pulmonary fibrosis ;
Systemic sclerosis |
Publicat a: |
International Journal of Technology Assessment in Health Care, Vol. 38 Núm. 1 (january 2022) , p. e64, ISSN 1471-6348 |
DOI: 10.1017/S0266462322000459
PMID: 35912833
El registre apareix a les col·leccions:
Documents de recerca >
Documents dels grups de recerca de la UAB >
Centres i grups de recerca (producció científica) >
Ciències de la salut i biociències >
Institut de Recerca Sant PauArticles >
Articles de recercaArticles >
Articles publicats
Registre creat el 2024-03-25, darrera modificació el 2024-05-28